Serum Institute Begins Phase Two And Phase Three Bridging Trials Of Covovax, Even As Roll Out Of Covishield Continues
Serum Institute Begins Phase Two And Three Bridging Trials Of Covid-19 Vaccine Candidate Covovax In IndiaSerum Institute of India (Pic Via Twitter)

In a boost to the national effort against the COVID-19 pandemic, the world's largest vaccine maker Serum Institute of India (SII) has started the phase two and three bridging trials of the Covovax Covid-19 vaccine candidate in India in a study that would involve 1,600 participants, reports Livemint.

The trials have begun at one of the sites in Pune, and at least one more site Delhi-based Hamdard Institute of Medical Sciences and Research is likely to begin screening for the vaccine candidate as early as upcoming Tuesday (30 March).

It should be noted that Covovax is SII's version of the vaccine developed by United States (US) based Novavax which had earlier this month announced that the vaccine has efficacy as high as 96 per cent against the original strain of the virus, as per the phase three study conducted in the United Kingdom (UK).

The company however has also reported, that its vaccine has an efficacy of 86.3 per cent against the UK mutant variant of the virus. On average, as per the company, the vaccine has an efficacy of 89.7 per cent.

Adar Poonawalla-led SII is already manufacturing pharmaceutical major AstraZeneca's vaccine under the name Covishield in India and is gearing to possibly launch Covovax by August. However, the company is planning to begin stockpiling the vaccine from April onwards to meet future demand.

An Appeal...

Dear Reader,

As you are no doubt aware, Swarajya is a media product that is directly dependent on support from its readers in the form of subscriptions. We do not have the muscle and backing of a large media conglomerate nor are we playing for the large advertisement sweep-stake.

Our business model is you and your subscription. And in challenging times like these, we need your support now more than ever.

We deliver over 10 - 15 high quality articles with expert insights and views. From 7AM in the morning to 10PM late night we operate to ensure you, the reader, get to see what is just right.

Becoming a Patron or a subscriber for as little as Rs 1200/year is the best way you can support our efforts.

Become A Patron
Become A Subscriber